Congratulations to Dr. Catherina Pinnaro (fellow in Endocrinology) for her recent $2,000 grant from the Lawson Wilkins Pediatric Endocrine Society. The funds will go towards studying “Genetic Modifiers of Glycemic Variability and CHD in Tumer Syndrome“.
The central administrative research support team for both bench and clinical research has moved from their previous space in GH SW 164-4 to BT 1115. BT 1115 is the space that also houses the Dunphy Conference Room.
Team members who have moved include Dan Benton, Lindsey Eckrich, Donna Friel and Angi Roemerman.
Background: Preterm infants are susceptible to unique pathology due to their immaturity. Mouse models are commonly used to study immature intestinal disease, including necrotizing enterocolitis (NEC). Current NEC models are performed at a variety of ages, but data directly comparing intestinal developmental stage equivalency between mice and humans are lacking.
Methods: Small intestines were harvested from C57BL/6 mice at 3–4 days intervals from birth to P28 (n = 8 at each age). Preterm human small intestine samples representing 17–23 weeks of completed gestation were obtained from the University of Pittsburgh Health Sciences Tissue Bank, and at term gestation during reanastamoses after resection for NEC (n = 4–7 at each age). Quantification of intestinal epithelial cell types and messenger RNA for marker genes were evaluated on both species.
Results: Overall, murine and human developmental trends over time are markedly similar. Murine intestine prior to P10 is most similar to human fetal intestine prior to viability. Murine intestine at P14 is most similar to human intestine at 22–23 weeks completed gestation, and P28 murine intestine is most similar to human term intestine.
Conclusion: Use of C57BL/6J mice to model the human immature intestine is reasonable, but the age of mouse chosen is a critical factor in model development.
The Research Development Office in the Office of the Vice President for Research, in collaboration with the Carver College of Medicine Office of Faculty Affairs and Development, would like to make you aware that Dr. John Robertson from Grant Writer’s Seminars and Workshops (GWSW) will conduct the Write Winning Grant Proposals seminar on Friday, October 25, 2019. The seminar is appropriate for faculty members, postdoctoral researchers and administrative staff who have had some exposure to writing grant applications, either through training / mentoring or personal experience. Please share this information with faculty and staff you think would benefit from this training. Additional details are below.
TITLE: Write Winning Grant Proposals
DATE: Friday, October 25, 2019
TIME: 8:30 AM – 4:30 PM (Check in opens at 7:45 AM)
PLACE: The Hilton Garden Inn, Iowa City (328 S. Clinton Street)
COST: $150/person (includes supplemental materials and lunch)
REGISTRATION DEADLINE: Friday, October 4, 2019 (close of business)
The Holden Comprehensive Cancer Center can submit two applications to the Curing Kids Cancer Grant mechanism. If you are interested in applying, please respond by Noon on Monday, July 1 with information on your proposed project, as per the terms of the grant. –Tami Thompson (email@example.com)
Internal Holden Comprehensive Cancer Center deadline Noon, Monday, July 1, 2019
Curing Kids Cancer – limited to two applications per institution.
Abstract: The objective of the current study was to develop a population pharmacokinetics (PK) model for erythropoietin (Epo) in premature infants and healthy adults to characterize the variation in PK, and to study the differences in Epo PK in these 2 populations. Thirteen very low-birth-weight premature infants (<1500 g at birth), and 10 healthy adults received up to 4 intravenous doses of Epo that ranged from 10 to 500 U/kg. The final model had a target-mediated saturable, nonlinear, elimination pathway that incorporated the mechanism of Epo binding to its receptors along with a parallel linear, central elimination pathway. Epo clearance was found to be significantly higher in preterm infants compared to adults. Epo clearance via the nonlinear pathway was found to be much higher in infants; they had an Epo receptor capacity of 133 pM vs 86.6 pM in adults, which is most likely due to the higher erythroid progenitor cell mass per kilogram of body weight in infants. The parallel linear elimination was found to be more dominant in adults, reaching 91% of the total clearance with a 500-U/kg dose compared to just 6.1% of the total clearance following the same dose in preterm infants. Thus, this mechanism-based population PK model revealed that receptor-based nonlinear elimination is the dominant Epo elimination pathway in premature infants, and parallel linear elimination is dominant in adults.
Congratulations to Dr. Polly Ferguson, Division Director of the Division of Rheumatology, for being co-author on some recent guidelines published for the American College of Rheumatology/Arthritis Foundation. The guidelines are below:
Calvin Carter, a post-doc research scholar in Dr. Sheffield’s lab, recently received a grant for “Glycemic Lowering Mechanisms of Low-Frequency Electromagnetic Fields in Mouse Models of Type 2 Diabetes” from the American Diabetes Association (ADA).
The award provides $61,388/year for 3 years, for a total of $190,413. Dr. Sheffield will serve as mentor on the project, with Calvin as the PI.
Congratulations to Dr. Chuck Grose in Pediatric Infectious Diseases for his new subcontract for “Identification and Characterization of Children with Asthma Associated Comorbidities Through Computational and Immune Phenotyping“.
The NIH-funded research was provided to Mayo Clinic, who then subcontracted with Dr. Grose for this portion of the grant. The grant provides $38,125/year for 4 years, for a total of $152,500. Congratulations, Dr. Grose!